ライフサイエンスコーパス: tenofovir

1 doses, thereby reducing systemic exposure to tenofovir.

2 n nucleoside reverse transcriptase inhibitor tenofovir.

3 the nucleos(t)ide analogs (NAs) entecavir or tenofovir.

4 ir, emtricitabine, tenofovir alafenamide, or tenofovir.

5 sitivity to elvitegravir, emtricitabine, and tenofovir.

6 rticipants were offered 1 year of open-label tenofovir.

7 pes showing sensitivity to emtricitabine and tenofovir.

8 ica, initiating ART in pregnancy (once-daily tenofovir 300 mg, emtricitabine 200 mg, and efavirenz 60

9 nrolment in the BTS, were offered daily oral tenofovir (300 mg) for 1 year at 17 Bangkok Metropolitan

10 Seven patients in the tenofovir alafenamide (2%) and three (1%) in the tenofov

11 ivirine (25 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg) or to continue a single-ta

12 ivirine (25 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg) or to remain on a single-t

13 coformulated bictegravir, emtricitabine, and tenofovir alafenamide (n=316) or coformulated dolutegrav

14 The TDF analogue tenofovir alafenamide (TAF) has demonstrated equal effic

15 Tenofovir alafenamide (TAF) is a novel prodrug of tenofo

16 used vaginally in HIV prevention trials, and Tenofovir alafenamide (TAF), an improved prodrug of TFV,

17 n serum creatinine was small in both groups (tenofovir alafenamide 0.01 mg/dL [95% CI 0.00 to 0.02] v

18 cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg (tenofovir alafenamide group

19 cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg once per day.

20 cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg, which was taken once per da

21 bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg or coformulated dolutegravir

22 bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg or dolutegravir 50 mg with c

23 status, to receive once-daily oral doses of tenofovir alafenamide 25 mg or tenofovir disoproxil fuma

24 g with coformulated emtricitabine 200 mg and tenofovir alafenamide 25 mg, with matching placebo, once

25 common adverse events overall were headache (tenofovir alafenamide 40 [14%] patients vs tenofovir dis

26 330 with dolutegravir plus emtricitabine and tenofovir alafenamide [dolutegravir group]).

27 coformulated bictegravir, emtricitabine, and tenofovir alafenamide achieved virological suppression i

28 ents were randomly assigned (285 assigned to tenofovir alafenamide and 141 assigned to tenofovir diso

29 ) and AST (20 [3%] of 577 patients receiving tenofovir alafenamide and 19 [7%] of 288 patients receiv

30 ssigned and 873 received treatment (581 with tenofovir alafenamide and 292 with tenofovir disoproxil

31 At week 48, 296 (94%) of 316 participants on tenofovir alafenamide and 294 (94%) of 313 on tenofovir

32 received bictegravir plus emtricitabine and tenofovir alafenamide and 33 received dolutegravir plus

33 s in ALT (62 [11%] of 577 patients receiving tenofovir alafenamide and 36 [13%] of 288 patients recei

34 ed (438 with rilpivirine, emtricitabine, and tenofovir alafenamide and 437 with efavirenz, emtricitab

35 RETATION: Bictegravir plus emtricitabine and tenofovir alafenamide and dolutegravir plus emtricitabin

36 14 (5%) patients receiving tenofovir alafenamide and nine (6%) patients receiving t

37 with the NRTI combination emtricitabine and tenofovir alafenamide as a fixed-dose combination to dol

38 tegravir coformulated with emtricitabine and tenofovir alafenamide as a fixed-dose combination versus

39 et darunavir, cobicistat, emtricitabine, and tenofovir alafenamide as a potential switch option for t

40 mide and dolutegravir plus emtricitabine and tenofovir alafenamide both showed high efficacy up to 24

41 n containing rilpivirine, emtricitabine, and tenofovir alafenamide compared with remaining on rilpivi

42 on-inferiority with a 10% efficacy margin of tenofovir alafenamide compared with tenofovir disoproxil

43 The novel prodrug tenofovir alafenamide delivers the nucleotide reverse tr

44 nt taking bictegravir plus emtricitabine and tenofovir alafenamide discontinued because of a drug-rel

45 coformulated bictegravir, emtricitabine, and tenofovir alafenamide does not require HLA B*5701 testin

46 nt (327 with bictegravir, emtricitabine, and tenofovir alafenamide fixed-dose combination [bictegravi

47 ombination of 200 mg emtricitabine and 25 mg tenofovir alafenamide for 48 weeks.

48 Switching to rilpivirine, emtricitabine, and tenofovir alafenamide from efavirenz, emtricitabine, and

49 Tenofovir alafenamide fumarate (TAF), a new prodrug of t

50 lated adverse events were more common in the tenofovir alafenamide group (204 patients [21%] vs 76 [1

51 630 participants were randomised (316 to the tenofovir alafenamide group and 314 to the tenofovir dis

52 959 patients were randomly assigned to the tenofovir alafenamide group and 477 to the tenofovir dis

53 314) in the bictegravir, emtricitabine, and tenofovir alafenamide group and 93.0% of patients (n=293

54 187 (32%) of 581 patients in the tenofovir alafenamide group and 96 (33%) of 292 patients

55 s maintained in 314 (94%) of patients in the tenofovir alafenamide group compared with 307 (93%) in t

56 had study-drug related adverse events in the tenofovir alafenamide group compared with 37 (12%) of 31

57 pants in the rilpivirine, emtricitabine, and tenofovir alafenamide group experienced treatment-relate

58 ts in the bictegravir plus emtricitabine and tenofovir alafenamide group versus 22 (67%) of 33 in the

59 ine 200 mg, and tenofovir alafenamide 10 mg (tenofovir alafenamide group) or to carry on taking one o

60 3 in the dolutegravir plus emtricitabine and tenofovir alafenamide group.

61 Patients given tenofovir alafenamide had a significantly smaller decrea

62 03 to 0.01]; p=0.32), but patients receiving tenofovir alafenamide had a smaller reduction in creatin

63 268 (94%) of 285 patients receiving tenofovir alafenamide had HBV DNA less than 29 IU/mL at

64 371 (64%) patients receiving tenofovir alafenamide had HBV DNA less than 29 IU/mL at

65 rmulation of rilpivirine, emtricitabine, and tenofovir alafenamide has recently been approved, and we

66 ty advantages, fixed-dose emtricitabine with tenofovir alafenamide has the potential to become an imp

67 elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-infected, treatment-naive a

68 Tenofovir alafenamide is a novel tenofovir prodrug that

69 elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide is a once-daily, integrase strand

70 Tenofovir alafenamide is a prodrug that reduces tenofovi

71 domly assigned (2:1) to receive either 25 mg tenofovir alafenamide or 300 mg tenofovir disoproxil fum

72 ose 200 mg emtricitabine with 10 mg or 25 mg tenofovir alafenamide or to continue 200 mg emtricitabin

73 94 (90%) of 438 participants assigned to the tenofovir alafenamide regimen and 402 (92%) of 437 assig

74 elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide regimen was well tolerated and ach

75 elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide regimen were similar to those prev

76 tients given bictegravir, emtricitabine, and tenofovir alafenamide than in those given dolutegravir,

77 common with bictegravir, emtricitabine, and tenofovir alafenamide than with dolutegravir, abacavir,

78 feriority of bictegravir, emtricitabine, and tenofovir alafenamide to dolutegravir, abacavir, and lam

79 CI -4.2 to 3.7), showing non-inferiority of tenofovir alafenamide to tenofovir disoproxil fumarate.

80 CI -2.5 to 5.1), showing non-inferiority of tenofovir alafenamide to tenofovir disproxil fumarate.

81 of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide versus continuing a regimen of boo

82 in patients switched to a regimen containing tenofovir alafenamide versus in those remaining on one c

83 infection (51 [9%] of 581 patients receiving tenofovir alafenamide vs 22 [8%] of 292 patients receivi

84 t of variation 58%), and the mean AUClast of tenofovir alafenamide was 333 ng x h/mL (45%).

85 In patients with HIV, tenofovir alafenamide was as efficacious as tenofovir di

86 elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide was efficacious and well tolerated

87 Switching to rilpivirine, emtricitabine, and tenofovir alafenamide was non-inferior to continuing ril

88 HBeAg-negative chronic HBV, the efficacy of tenofovir alafenamide was non-inferior to that of tenofo

89 mbination of bictegravir, emtricitabine, and tenofovir alafenamide was safe and well tolerated compar

90 Bictegravir, emtricitabine, and tenofovir alafenamide was safe and well tolerated with b

91 elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide were higher, but modestly so, than

92 received dolutegravir plus emtricitabine and tenofovir alafenamide).

93 Tenofovir alafenamide, a tenofovir prodrug, results in 9

94 ir disoproxil fumarate to emtricitabine with tenofovir alafenamide, high rates of virological suppres

95 ast quantifiable concentration (AUClast) for tenofovir alafenamide, incidence of treatment-emergent s

96 tions with the backbone of emtricitabine and tenofovir alafenamide, might provide an advantage to pat

97 f resistance to elvitegravir, emtricitabine, tenofovir alafenamide, or tenofovir.

98 last quantifiable concentration (AUClast) of tenofovir alafenamide, treatment-emergent serious advers

99 ese findings support guidelines recommending tenofovir alafenamide-based regimens, including coformul

100 Switching to a tenofovir alafenamide-containing regimen from one contai

101 us RNA suppression while receiving a TDF- or tenofovir alafenamide-containing regimen.

102 rev, showed no impact on response to TDF- or tenofovir alafenamide-containing regimens.

103 cobicistat, 200 mg emtricitabine, and 10 mg tenofovir alafenamide.

104 nistered with coformulated emtricitabine and tenofovir alafenamide.

105 breast milk concentration ratios of 1.0 for tenofovir and 0.8 for emtricitabine, respectively.

106 breast milk were 3.3 ng/mL (2.3 to 4.4) for tenofovir and 183.0 ng/mL (113.0 to 250.0) for emtricita

107 breast milk were 3.2 ng/mL (2.3 to 4.7) for tenofovir and 212.5 ng/mL (140.0 to 405.0) for emtricita

108 ts a linear range between 1 nM and 100 nM of tenofovir and a limit of detection of 1.2 nM.

109 alafenamide fumarate (TAF), a new prodrug of tenofovir and a potential successor of tenofovir disopro

110 week, as estimated by hair concentrations of tenofovir and emtricitabine (ptrend=0.008).

111 We investigated whether tenofovir and emtricitabine are excreted into breast mil

112 ants, hair samples were collected to measure tenofovir and emtricitabine concentrations (a measure of

113 Tenofovir and emtricitabine concentrations were quantifi

114 d resultant infant plasma concentrations for tenofovir and emtricitabine were 12,500 and >200-fold lo

115 er tenofovir monotherapy or a combination of tenofovir and emtricitabine) in HIV serodiscordant coupl

116 sion of the K65R increased susceptibility to tenofovir and other nucleosides, while reversion of the

117 algorithm (eg, zidovudine after failure with tenofovir and vice versa; NRTI group).

118 ally, we find that although viruses from the tenofovir arm were 2-fold less infectious, they replicat

119 s associated with the decision to take daily tenofovir as PrEP, the decision to return for at least o

120 ropensity for these viruses to develop a key tenofovir-associated resistance mutation.

121 here were no significant differences between tenofovir-based ART and zidovudine alone (P=0.10 and P=0

122 normal blood chemical values was higher with tenofovir-based ART than with zidovudine alone (2.9% vs.

123 Tenofovir-based ART was associated with higher rates tha

124 Daily oral tenofovir-based pre-exposure prophylaxis (PrEP) is high

125 t-acting antivirals for HCV and wider use of tenofovir-based regimens for HBV should be prioritized f

126 and other anaerobic bacteria, which depleted tenofovir by metabolism more rapidly than target cells c

127 ing preexposure prophylaxis (PrEP) with oral tenofovir can induce SIV immunity without productive inf

128 Plasma tenofovir concentrations demonstrated poor adherence to

129 is delta virus (HDV) viral loads (VL) during tenofovir-containing antiretroviral therapy among patien

130 ients with virological failure of first-line tenofovir-containing ART.

131 m the United Kingdom who received a standard tenofovir-containing first-line regimen and were followe

132 n in patients who have failure of first-line tenofovir-containing regimens in sub-Saharan Africa, and

133 Concern has been expressed that tenofovir-containing regimens may have reduced effective

134 f 712 individuals with failure of first-line tenofovir-containing regimens, 115 (16%) had at least on

135 thout TAMs for the presence of resistance to tenofovir, cytosine analogue, or NNRTIs.

136 kok Tenofovir Study (BTS) showed that taking tenofovir daily as pre-exposure prophylaxis (PrEP) can r

137 nal bacteria to microbicide efficacy through tenofovir depletion via bacterial metabolism.

138 .038); the relative risk among those having tenofovir detected at 3 months was 0.40 (P = .045).

139 a prevention effect among those ever having tenofovir detected was 0.53 (P = .038); the relative ris

140 In SP, both RPV and EVGcobi, associated to tenofovir-DF and emtricitabine, behave similarly and ach

141 ir, emtricitabine, their active metabolites (tenofovir diphosphate [TFVdp] and emtricitabine triphosp

142 Tenofovir diphosphate concentrations in dried blood spot

143 dequate long-term adherence, as evidenced by tenofovir diphosphate concentrations in dried blood spot

144 idenced by repeatedly high concentrations of tenofovir diphosphate in dried blood spots.

145 , rates of adherence, and measured levels of tenofovir diphosphate in dried blood spots; and (3) exam

146 Tenofovir diphosphate levels consistent with a high degr

147 odrug of tenofovir that efficiently delivers tenofovir diphosphate to lymphoid cells following oral a

148 Tenofovir-diphosphate (TFV-DP) in red blood cells was us

149 mly assigned (1:1) to receive daily combined tenofovir disoproxil fumarate (245 mg) and emtricitabine

150 rticipants were given combination tablets of tenofovir disoproxil fumarate (300 mg) and emtricitabine

151 ivirine (25 mg), emtricitabine (200 mg), and tenofovir disoproxil fumarate (300 mg), with matching pl

152 virenz (600 mg), emtricitabine (200 mg), and tenofovir disoproxil fumarate (300 mg), with matching pl

153 elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (combined ART).

154 8 versus 130 (93%) of 140 patients receiving tenofovir disoproxil fumarate (difference 1.8% [95% CI -

155 elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (integrase inhibitor regim

156 o 100 mg, 67 to 200 mg, and 66 to 400 mg) or tenofovir disoproxil fumarate (n=101).

157 ir-boosted atazanavir with emtricitabine and tenofovir disoproxil fumarate (protease inhibitor based

158 After adjustment, persons who had ever used tenofovir disoproxil fumarate (TDF) (1.40; 1.15-1.70) or

159 viral therapy currently receive some form of tenofovir disoproxil fumarate (TDF) as part of their HIV

160 Despite widespread use of tenofovir disoproxil fumarate (TDF) in pregnant and brea

161 Tenofovir disoproxil fumarate (TDF) is associated with p

162 Tenofovir disoproxil fumarate (TDF) is commonly used in

163 Exposure to tenofovir disoproxil fumarate (TDF) may cause renal toxi

164 Clinical studies of systemic tenofovir disoproxil fumarate (TDF) PrEP revealed reduce

165 differ among patients receiving LDV/SOF and tenofovir disoproxil fumarate (TDF) without a protease i

166 lone, MVC plus emtricitabine (FTC), MVC plus tenofovir disoproxil fumarate (TDF), and TDF plus FTC.

167 MVC only, MVC-emtricitabine (FTC), MVC-tenofovir disoproxil fumarate (TDF), and TDF-FTC (contro

168 nd 7 had M184V/I (0.1%), despite high use of tenofovir disoproxil fumarate (TDF), emtricitabine, and

169 ug of tenofovir and a potential successor of tenofovir disoproxil fumarate (TDF), has been approved i

170 importance of renal and endocrine changes in tenofovir disoproxil fumarate (TDF)-related bone toxicit

171 cluding the clinically approved formulation, tenofovir disoproxil fumarate (TDF).

172 fenamide 0.01 mg/dL [95% CI 0.00 to 0.02] vs tenofovir disoproxil fumarate 0.02 mg/dL [0.00 to 0.04],

173 (tenofovir alafenamide 40 [14%] patients vs tenofovir disoproxil fumarate 14 [10%] patients), nasoph

174 oral doses of tenofovir alafenamide 25 mg or tenofovir disoproxil fumarate 300 mg, each with matching

175 ) ritonavir (RTV) or standard of care (SOC) (tenofovir disoproxil fumarate 300 mg, emtricitabine 200

176 Daily, oral use of tenofovir disoproxil fumarate and emtricitabine (TDF-FTC

177 tonavir-boosted atazanavir plus coformulated tenofovir disoproxil fumarate and emtricitabine once a d

178 th darunavir/ritonavir and 2 nucleos(t)ides (tenofovir disoproxil fumarate and emtricitabine or abaca

179 g (one tablet) orally twice daily, each with tenofovir disoproxil fumarate and emtricitabine orally o

180 atinine clearance and the number of doses of tenofovir disoproxil fumarate and emtricitabine taken pe

181 BMS-986001 had similar efficacy to that of tenofovir disoproxil fumarate and was associated with a

182 /ADAPT) of oral PrEP with emtricitabine plus tenofovir disoproxil fumarate at a research centre in Ca

183 elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate compared with a boosted pr

184 disoproxil fumarate; one patient assigned to tenofovir disoproxil fumarate did not receive the treatm

185 men and had been on daily emtricitabine and tenofovir disoproxil fumarate for 8 months presented wit

186 s per mL) on rilpivirine, emtricitabine, and tenofovir disoproxil fumarate for at least 6 months befo

187 ies per mL) on efavirenz, emtricitabine, and tenofovir disoproxil fumarate for at least 6 months befo

188 enamide group compared with 307 (93%) in the tenofovir disoproxil fumarate group (difference 1.3%, 95

189 per mL, compared with 88 (89%) of 99 in the tenofovir disoproxil fumarate group (modified intention-

190 lated to study treatment; one patient in the tenofovir disoproxil fumarate group died, but this was n

191 fovir alafenamide (2%) and three (1%) in the tenofovir disoproxil fumarate group discontinued due to

192 de group and 96 (33%) of 292 patients in the tenofovir disoproxil fumarate group had grade 3 or 4 lab

193 vir disoproxil fumarate-containing regimens (tenofovir disoproxil fumarate group) for 96 weeks.

194 e tenofovir alafenamide group and 314 to the tenofovir disoproxil fumarate group).

195 e tenofovir alafenamide group and 477 to the tenofovir disoproxil fumarate group.

196 of 437 in the efavirenz, emtricitabine, and tenofovir disoproxil fumarate group.

197 e group compared with 37 (12%) of 314 in the tenofovir disoproxil fumarate group; none of these were

198 enofovir alafenamide and 294 (94%) of 313 on tenofovir disoproxil fumarate had maintained less than 5

199 alafenamide and nine (6%) patients receiving tenofovir disoproxil fumarate had serious adverse events

200 Antiretroviral regimens containing tenofovir disoproxil fumarate have been associated with

201 or to continuing rilpivirine, emtricitabine, tenofovir disoproxil fumarate in maintaining viral suppr

202 ily use of PrEP with oral emtricitabine plus tenofovir disoproxil fumarate in women.

203 re prophylaxis (PrEP) with emtricitabine and tenofovir disoproxil fumarate is highly effective agains

204 SVR12 among patients receiving either tenofovir disoproxil fumarate or abacavir as part of the

205 l tissue exposure by the third daily dose of tenofovir disoproxil fumarate plus emtricitabine.

206 regimen and 402 (92%) of 437 assigned to the tenofovir disoproxil fumarate regimen (difference -2.0%,

207 eived one dose of study drug and were on the tenofovir disoproxil fumarate regimen before screening w

208 n patients switching from emtricitabine with tenofovir disoproxil fumarate to emtricitabine with teno

209 amide-containing regimen from one containing tenofovir disoproxil fumarate was non-inferior for maint

210 afenamide from efavirenz, emtricitabine, and tenofovir disoproxil fumarate was non-inferior in mainta

211 erior to the 195 (67%) of patients receiving tenofovir disoproxil fumarate who had HBV DNA less than

212 either 25 mg tenofovir alafenamide or 300 mg tenofovir disoproxil fumarate with matching placebo.

213 amide and 36 [13%] of 288 patients receiving tenofovir disoproxil fumarate) and AST (20 [3%] of 577 p

214 ndividuals on cART (predominantly containing tenofovir disoproxil fumarate) were also more likely to

215 enamide vs 22 [8%] of 292 patients receiving tenofovir disoproxil fumarate), nasopharyngitis (56 [10%

216 amide and 437 with efavirenz, emtricitabine, tenofovir disoproxil fumarate).

217 men (both regimens include emtricitabine and tenofovir disoproxil fumarate).

218 (581 with tenofovir alafenamide and 292 with tenofovir disoproxil fumarate).

219 namide and 19 [7%] of 288 patients receiving tenofovir disoproxil fumarate).

220 ovir alafenamide was non-inferior to that of tenofovir disoproxil fumarate, and had improved bone and

221 wer among infants exposed from conception to tenofovir disoproxil fumarate, emtricitabine, and efavir

222 Compared with tenofovir disoproxil fumarate, individuals in the BMS-98

223 of 99 and one (1%) of 99 patients receiving tenofovir disoproxil fumarate, respectively.

224 e increased for up to 6 years of exposure to tenofovir disoproxil fumarate, ritonavir-boosted atazana

225 r plasma concentrations by 90% compared with tenofovir disoproxil fumarate, thereby decreasing bone a

226 cells more efficiently at a lower dose than tenofovir disoproxil fumarate, thereby reducing systemic

227 e 200 mg emtricitabine with 200 mg or 300 mg tenofovir disoproxil fumarate, while remaining on the sa

228 tenofovir alafenamide was as efficacious as tenofovir disoproxil fumarate, with reduced bone and ren

229 lso extend to HIV-negative individuals using tenofovir disoproxil fumarate-based pre-exposure prophyl

230 Nearly all (97.6%) patients received tenofovir disoproxil fumarate-containing ART, in line wi

231 ) or to carry on taking one of four previous tenofovir disoproxil fumarate-containing regimens (tenof

232 remaining on rilpivirine, emtricitabine, and tenofovir disoproxil fumarate.

233 ir-boosted atazanavir with emtricitabine and tenofovir disoproxil fumarate.

234 versus in those remaining on one containing tenofovir disoproxil fumarate.

235 argin of tenofovir alafenamide compared with tenofovir disoproxil fumarate.

236 osted protease inhibitor, emtricitabine, and tenofovir disoproxil fumarate.

237 n coformulated efavirenz, emtricitabine, and tenofovir disoproxil fumarate.

238 despite consistent use of emtricitabine and tenofovir disoproxil fumarate.

239 non-inferiority of tenofovir alafenamide to tenofovir disoproxil fumarate.

240 phylaxis (PrEP) interventions worldwide, yet tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) fo

241 to tenofovir alafenamide and 141 assigned to tenofovir disoproxil fumarate; one patient assigned to t

242 articipants were randomized 1:1:1 to receive tenofovir-disoproxil fumarate (DF) plus emtricitabine, a

243 Tenofovir disoproxyl fumarate (TDF) disoproxyl fumarate

244 er tenofovir plasma concentrations than does tenofovir disproxil fumarate, thereby minimising bone an

245 non-inferiority of tenofovir alafenamide to tenofovir disproxil fumarate.

246 l clinics for ART (fixed-dose combination of tenofovir, emtricitabine, and efavirenz) regardless of C

247 y measuring mucosal tissue concentrations of tenofovir, emtricitabine, their active metabolites (teno

248 The patients were randomized to tenofovir-emtricitabine (TDF/FTC) plus atazanavir-ritona

249 In this high incidence population, daily tenofovir-emtricitabine conferred even higher protection

250 sed antiretroviral therapy (ART) with either tenofovir-emtricitabine or lamivudine (tenofovir group)

251 rticipants were randomly assigned to receive tenofovir-emtricitabine plus either atazanavir/ritonavir

252 Both participants initiated PrEP with tenofovir/emtricitabine during very early Fiebig stage I

253 Tenofovir/emtricitabine HIV prevention trials among wome

254 HIV-infected patients on EFV plus tenofovir/emtricitabine or abacavir/lamivudine with NAFL

255 V initiating ART with atazanavir/ritonavir + tenofovir/emtricitabine to a single zoledronic acid (ZOL

256 the HCC incidence beyond year 5 of entecavir/tenofovir (ETV/TDF) therapy and tried to determine possi

257 sexual event-based use of emtricitabine and tenofovir for MSM who had condomless anal sexual interco

258 th comparison of adherent individuals in the tenofovir gel arm to placebo recipients was nearly elimi

259 This indicates that the use of tenofovir gel did not select for viral variants with hig

260 tigated whether vaginal microbiota modulated tenofovir gel microbicide efficacy in the CAPRISA (Centr

261 nts were evaluated; 1484 (26.8%) were in the tenofovir group and 4063 (73.2%) were in the zidovudine

262 ither tenofovir-emtricitabine or lamivudine (tenofovir group) or zidovudine-lamivudine (zidovudine gr

263 otypes showing sensitivity to emtricitabine, tenofovir, lamivudine, and abacavir; and an estimated gl

264 pared with zidovudine-lamivudine, the use of tenofovir-lamivudine or emtricitabine in combination wit

265 Once generic coformulations of tenofovir/lamivudine become accessible, however, the app

266 n women who seroconverted in the CAPRISA 004 tenofovir microbicide trial.

267 -controlled trial of daily oral PrEP (either tenofovir monotherapy or a combination of tenofovir and

268 ofovir alafenamide is a prodrug that reduces tenofovir plasma concentrations by 90% compared with ten

269 de is a novel tenofovir prodrug that reduces tenofovir plasma concentrations by 90%, thereby decreasi

270 e, a tenofovir prodrug, results in 90% lower tenofovir plasma concentrations than does tenofovir disp

271 ned viral failure on first-line therapy with tenofovir plus a cytosine analogue (lamivudine or emtric

272 osted lopinavir, combined with zidovudine or tenofovir plus lamivudine or emtricitabine.

273 Tenofovir alafenamide is a novel tenofovir prodrug that reduces tenofovir plasma concentr

274 Tenofovir alafenamide, a tenofovir prodrug, results in 90% lower tenofovir plasma

275 d the DRMs that emerge in patients receiving tenofovir prodrugs, the nonnucleoside reverse transcript

276 Tenofovir reduced HIV incidence by 61% (P = 0.013) in La

277 In the adjusted model, tenofovir regimen (hazard ratio [HR], 1.47; 95% confiden

278 TAMs; p=0.007) and were more likely to have tenofovir resistance (93 [81%] of 115 patients with TAMs

279 the study-level proportion of patients with tenofovir resistance and TAMs was 0.64 (p<0.0001), and t

280 was 0.64 (p<0.0001), and the odds ratio for tenofovir resistance comparing patients with and without

281 Despite K65R with the T69del in 9 samples, tenofovir retained activity in >60%.

282 ed, double-blind, placebo-controlled Bangkok Tenofovir Study (BTS) showed that taking tenofovir daily

283 /FTC Oral HIV Prophylaxis Trial, the Bangkok Tenofovir Study, and the Bangkok MSM Cohort Study, 3 sep

284 dine (3TC), and the nucleotide RTI inhibitor tenofovir (TDF), show efficacy in blocking K103 RT.

285 y and increased rescue efficiency on AZT- or tenofovir-terminated primers, as compared with the doubl

286 ng rectally applied reduced-glycerin (RG) 1% tenofovir (TFV) and oral emtricitabine/TFV disoproxil fu

287 The pharmacokinetic properties of tenofovir (TFV) and other charged nucleoside analogues a

288 us to evaluate the effects of progestins on tenofovir (TFV) and TFV-alafenamide (TAF) on HIV infecti

289 )-infected women virologically suppressed on tenofovir (TFV) disoproxil fumarate/emtricitabine and ri

290 Despite the therapeutic success of tenofovir (TFV) for treatment of HIV-1 infection, numero

291 PK-PD modeling of tenofovir (TFV) in plasma, female reproductive tract tis

292 This is particularly true for tenofovir (TFV), adefovir, and other antiviral nucleosid

293 Here we determined whether Tenofovir (TFV), used vaginally in HIV prevention trials

294 ovir alafenamide (TAF) is a novel prodrug of tenofovir that efficiently delivers tenofovir diphosphat

295 e nucleotide reverse transcriptase inhibitor tenofovir to target cells more efficiently at a lower do

296 No serious adverse events related to tenofovir use were reported.

297 Detectible mucosal tenofovir was lower in non-Lactobacillus women, negative

298 ctive proposed infant therapeutic doses, and tenofovir was not detected in 94% of infant plasma sampl

299 In infant plasma, tenofovir was unquantifiable in 46/49 samples (94%), but

300 The drug tenofovir was used as a model small molecule.